Table 3.
Mean changes in primary and secondary endpoints from baseline to week 12.
| BotxA (n=20), mean (±SD) | Placebo (n=18), mean (±SD) | P | |
|---|---|---|---|
| Visual analogical score | |||
| Baseline | 6.90 (1.37) | 7.78 (1.59) | 0.08 |
| 4 weeks | 3.60 (2.16) | 5.83 (1.94) | <0.01 |
| 8 weeks | 3.05 (2.62) | 6.55 (2.23) | <0.01 |
| 12 weeks | 3.45 (2.39) | 6.17 (2.50) | <0.01 |
| Headache episodes with allodynia | |||
| Baseline | 12.1 | 17.00 (9.69) | 0.12 |
| 4 weeks | 5.65 (4.89) | 9.61 (5.24) | 0.02 |
| 8 weeks | 4.30 (3.99) | 11.94 (6.83) | P<0.01 |
| 12 weeks | 5.20 (6.76) | 11.17 (6.69) | 0.01 |
| Frequency of analgesic use for headache | |||
| Baseline | 11.65 (13.86) | 18.33 (12.97) | 0.13 |
| 4 weeks | 3.75 (4.65) | 8.72 (4.93) | P<0.01 |
| 8 weeks | 3.70 (5.02) | 9.17 (6.77) | P<0.01 |
| 12 weeks | 4.25 (6.95) | 10.22 (6.11) | P<0.01 |